title: Malaria medicines: a glass half full?
abstract: Despite substantial scientific progress over the past two decades, malaria remains a worldwide burden that causes hundreds of thousands of deaths every year. New, affordable and safe drugs are required to overcome increasing resistance against artemisinin-based treatments, treat vulnerable populations, interrupt the parasite life cycle by blocking transmission to the vectors, prevent infection and target malaria species that transiently remain dormant in the liver. In this Review, we discuss how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.
authors.affiliation: Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland.
authors.forename: Timothy N C
authors.initials: TN
authors.lastname: Wells
authors.affiliation: Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland.
authors.forename: Rob
authors.initials: R
authors.lastname: Hooft van Huijsduijnen
authors.affiliation: 1] Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland. [2] Division of Allergy and Infectious Diseases, Department of Medicine and Departments of Global Health and Microbiology, University of Washington, 750 Republican Street, Seattle, Washington 98195, USA.
authors.forename: Wesley C
authors.initials: WC
authors.lastname: Van Voorhis
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D055808:Drug Discovery / Q000639:trends*; D014943:Global Health / Q000639:trends*; D006801:Humans; D008288:Malaria / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D000962:Antimalarials